Your end-of-week digest highlighting the most important developments in biotech, medtech, and pharma. The BioMed Nexus Weekly Roundup brings together the biggest approvals, trial readouts, financing moves, deals, and industry trends so you always see the full picture.
Last week delivered a regulatory reckoning that reshaped biotech valuation frameworks: the FDA rejected Disc Medicine’s bitopertin despite meeting its primary endpoint, issued a Refusal-to-File
Cytokinetics wins FDA approval for Myqorzo (aficamten) late Friday validating next-generation cardiac myosin inhibitor class and setting up heavyweight 2026 commercial battle with Bristol Myers
BioCryst pediatric Orladeyo approved but stock fades flat (-0.1%) on “sell the news” despite $200M incremental revenue potential, Innoviva Zoliflodacin (Nuzolvence) wins first-in-class oral gonorrhea
Vertex Casgevy achieves 100% efficacy in pediatric sickle cell, Arcellx Anito-cel demonstrates cleaner safety profile challenging Carvykti, Lilly’s Jaypirca wins head-to-head vs. Imbruvica, Structure oral
Itvisma breaks age barrier for SMA, Abbott corrects 3M Libre 3 sensors while pursuing $23B Exact Sciences acquisition, Hong Kong approves BCMA CAR-T, and biomimetics
Read time: 12 minutes Executive Summary Abbott’s blockbuster $23 billion takeover of Exact Sciences, combined with two precision oncology FDA approvals, marks a pivotal week
Pfizer’s $10B Metsera acquisition caps obesity bidding war; Merck bets $9.2B on Cidara’s long-acting flu antibody; FDA adds boxed warning to Elevidys gene therapy; surgical
Healthcare markets exploded with deal-making activity as November opened with a bang. Novartis dropped $12 billion to acquire Avidity Biosciences, Novo Nordisk and Pfizer escalated
The healthcare sector delivered a remarkable week of innovation, deal-making, and regulatory transformation. From the FDA’s groundbreaking National Priority Review program to over $6.4 billion
Markets experienced significant turbulence this week as banking sector concerns collided with healthcare earnings, policy developments, and robust deal-making activity. Here’s everything you need to
